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Founder BRCA1/2 Mutations among Male Patients
with Breast Cancer in Israel
To the Editor:
Germline mutations in the BRCA1 (MIM 113705) and
BRCA2 (MIM 600185) genes are associated with a high
risk of breast and ovarian cancer in women (Ford et al.
1998). The risk of male breast cancer is higher among
carriers of BRCA2 mutations compared with carriers of
BRCA1 mutations, although the absolute risk to male
carriers is not well characterized (Wooster et al. 1995;
Ford et al. 1998). Studies ofBRCA2 in small population-
and clinic-based series of male breast cancer patients
from the United States and the United Kingdom have
found carrier frequencies of 4%–14% (Couch et al.
1996; Friedman et al. 1997; Mavraki et al. 1997). Car-
rier frequencies for specific founder BRCA2 germline
mutations have been higher: 21%–40% (Thorlacius et
al. 1996; Haraldsson et al. 1998; Csokay et al. 1999).
The number of cases analyzed has ranged from 18 to
54, however, and the confidence limits on the carrier
frequencies are very large. Among predominantly Ash-
kenazi Jewish populations, three founder mutations in
the BRCA1/2 genes are present in 12% of all individuals,
and they may account for ∼80% of all the mutations in
these genes (Struewing et al. 1997; Frank et al. 1998).
This allows the relatively efficient analysis of larger num-
bers of cases.
All male patients with breast cancer ( ) diag-n = 165
nosed in five Israeli hospitals during 1980–97 were re-
viewed for inclusion in this study. Jewish patients were
characterized as Ashkenazi or non-Ashkenazi, on the
basis of either the recorded place of birth in the Israeli
Population Registry or, if they were born in Israel, their
father’s recorded place of birth. Non-Ashkenazi Jews
were born in Turkey, Syria, Iraq, Iran, Afghanistan, Mo-
rocco, or Libya. Israeli-born non-Jews were designated
as Arab, Christian, or Druze. Samples were analyzed
anonymously. Among the 122 histologically verified
cases for whom adequate pathological material could be
obtained, 1 was excluded, because analysis from mul-
tiple specimens differed with respect to mutation status
and marker genotypes. Eighty-nine cases were Ashke-
nazi, 21 were non-Ashkenazi, and 14 were Arabs.
Unstained 5-mm paraffin sections were scraped from
slides and were digested in 100 ml of buffer containing
10 mM Tris (pH 8.0), 50 mM KCl, 10 mM EDTA, 2
mM MgCl2, 1% Tween-20 and 10 mg of Proteinase K
at 57C overnight. The samples were then heated to
100C for 5 min and then 1–5 ml were used as template
in the PCR reactions. A 20-ml multiplex PCR reaction
was used to amplify the three segments containing the
founder mutations. Each reaction contained 1 # PCR
Buffer, 2.5 mM MgCl2, 100 mM each dNTP, 15% su-
crose, and 0.75 U Taq Gold (PE Biosystems). Primers
included 300 nM 2F103 (6FAM-tcgcgttgaagaagta-
caaaatgtc), 300 nM 2R102 (caaattaatacactcttgtgctgact-
tac), 200 nM 20F101 (HEX-gtcaatggaagaaaccac-
caaggtc), 200 nM 20R101 (tgcaaaggggagtggaatacacagt),
200 nM 11F101 (TET-tagggaagcttcataagtcagt
ctca), and 200 nM 11R101 (cttgcgttttgtaatgaagcatct).
Cycling consisted of 94C for 12 min, followed by 10
cycles of 92C for 10 s, annealing at 68C for 10 s, and
72C for 20 s, with the annealing temperature being
decreased 1.5C per cycle, followed by 30 cycles of 92C
for 15 s, 55C for 15 s, and 72C for 30 s, followed by
72C for 10 min. The PCR products were diluted 1:149
with water and then were diluted 1:6 with loading cock-
tail, according to the manufacturers’ recommendations,
and were electrophoresed on an ABI 310 capillary elec-
trophoresis machine by use of GENESCAN software (PE
Biosystems). Known mutant, wild-type, and no-DNA
controls were run with each PCR reaction. Mutants were
identified by visual inspection of the electropherograms,
with the small-insertion or -deletion mutations resulting
in an extra peak in the pattern. Primers to amplify the
chromosome 13 markers D13S260, D13S1695,
D13S1698, and D13S1701 were redesigned to result in
shorter amplicons. All carriers of the 6174delT muta-
tion and a reference family with this mutation were an-
alyzed for these four markers, on the ABI 310 (primer
sequences are available, on request, from the corre-
sponding author.)
The results of mutation testing are shown in table 1.
Of the 19 mutation carriers, 17 were Ashkenazi and 2
were non-Ashkenazi Jews. Carrier frequencies were not
statistically different between the two ethnic groups
( ). None of the Arab men was a carrier, and theP = .7
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Table 1
Israeli Male-Breast-Cancer Mutation Testing Results
POPULATION
NO.
TESTED
NO. (%) POSITIVE FOR MUTATION [95% CLS]
BRCA1 BRCA2
Total185delAG 5382insC 6174delT
Jews:
All 110 4 (3.6) [1, 9] 0 15 (13.6) [8, 21] 19 (17.3) [11, 26]
Ashkenazi 89 4 (4.5) [1, 11] 0 13 (14.6) [8, 24] 17 (19.1) [12, 29]
Sephardic 21 0 0 2 (9.5) [1, 30] 2 (9.5) [1, 30]
Arabs 14 0 0 0 0
5382insC mutation was not detected in any patients.
The mean ages at diagnosis of all 19 mutation carriers
(64 years) and of the BRCA2 6174delT mutation car-
riers (66 years) were not significantly different than that
of noncarriers (68 years). Reliable genotypes could not
be obtained for all the markers for all carriers, but 14
of 14 carriers successfully genotyped at D13S1698
shared the same allele as was seen in the reference family;
12 of 12 carriers successfully genotyped at D13S260
shared the correct allele; 7 of 8 carriers successfully gen-
otyped at D13S1701 shared the correct allele; and 13
of 15 carriers successfully genotyped at D13S1695
shared the correct allele.
These results suggest that 17% of Jewish men di-
agnosed with breast cancer in Israel carry a mutation in
BRCA1 or BRCA2, since only the three common foun-
der mutations were screened. This study was based on
the analysis of a small amount of pathological tissue,
and the proportion of the tissue that was tumor was
unknown. Our methods may have led both to false neg-
atives, caused by the complete loss of the relevant genes
in a tumor—although this might be expected to result
in preferential loss of the wild-type and retention of the
mutant allele—and false positives, caused by contami-
nation of the specimens during processing and handling.
Our observed carrier frequency is somewhat higher than
those in most series studied in the United States and the
United Kingdom but is lower than frequencies observed
in several other populations with common founder mu-
tations. Unlike that in female carriers, who have an ear-
lier age at diagnosis of breast cancer, the age at diagnosis
among male carriers was not significantly lower than
among noncarriers. This may reflect the fact that most
men carried a BRCA2 mutation, because the age at di-
agnosis for female breast cancer appears to be later for
BRCA2 carriers than for BRCA1 carriers (Ford et al.
1998).
The BRCA1 185delAG founder mutation has been
observed in both Ashkenazi and non-Ashkenazi Jewish
women with breast or ovarian cancer (Bar-Sade et al.
1998). We observed the 6174delT mutation in two non-
Ashkenazi Jewish men with breast cancer, and this is the
first published observation of this mutation in this pop-
ulation (Neuhausen et al. 1998). Our characterization
of Jewish men as Ashkenazi or non-Ashkenazi was based
on the place of birth as recorded in the Israeli Population
Registry. Since ethnic origin was not determined in per-
son or by biological testing, some misclassification could
have occurred. If verified in other studies, however, this
finding would suggest that this mutation is considerably
older than previously estimated (Neuhausen et al. 1998).
Genotyping of four microsatellite markers near BRCA2
was consistent with their sharing the same haplotype as
was seen in Ashkenazi carriers of this mutation. Al-
though the number of cases was small, we did not ob-
serve an earlier age at onset among mutation carriers,
nor did we detect any of the three mutations in Arab
men with breast cancer.
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